SANUWAVE Health, Inc. (SNWV)
SANUWAVE Health, Inc. (SNWV)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Gain on lease modification | NaN | 0 | 7 | NaN |
| Net loss | -1,439 | 6,109 | 10,325 | -4,621 |
| Accrued interest and accrued interest, related parties | NaN | 0 | 0 | 0 |
| Stock-based compensation | 1,611 | 1,337 | 1,407 | 2,106 |
| Proceeds from tenant improvement funds | NaN | 0 | 157 | 429 |
| Depreciation and amortization | 294 | 340 | 246 | 388 |
| Amortization of right-of-use leases | 18 | 41 | 83 | 185 |
| Provision for credit losses | 40 | 90 | -19 | 131 |
| Loss on disposal and impairment of assets | NaN | 0 | -210 | NaN |
| Loss (gain) on extinguishment of debt | NaN | 0 | -477 | 0 |
| Shares issued for services | 97 | NaN | NaN | NaN |
| Change in fair value of derivative liabilities | 0 | -5,921 | -6,097 | 3,911 |
| Gain on sale of patents | NaN | 375 | 5,000 | NaN |
| Amortization of debt issuance and debt discounts | 57 | 45 | 354 | 1,062 |
| Write-off of inventory | 69 | 498 | NaN | NaN |
| Loss on disposal of assets | -6 | NaN | NaN | NaN |
| Accounts receivable | 617 | 909 | 737 | 650 |
| Inventory | 39 | -382 | 903 | 1,762 |
| Prepaid expenses and other assets | -78 | -285 | -222 | 1,231 |
| Accounts payable | 54 | -785 | -10 | 274 |
| Accrued expenses and contract liabilities | 205 | 2,259 | 452 | -746 |
| Operating leases | 37 | 77 | 79 | NaN |
| Net cash provided by (used in) operating activities | 397 | 3,319 | 1,081 | -524 |
| Purchase of property and equipment | 23 | 96 | 525 | 1,321 |
| Deposits on property and equipment | 66 | NaN | NaN | NaN |
| Proceeds from sale of patents | NaN | 375 | 5,000 | NaN |
| Investment in software development | 69 | NaN | NaN | NaN |
| Net cash used in investing activities | -158 | 279 | 4,475 | -1,321 |
| Proceeds from secured term loan | NaN | 0 | 23,000 | NaN |
| Proceeds from secured revolving credit facility | NaN | 0 | 655 | NaN |
| Payment of note payable | NaN | 0 | 27,747 | 0 |
| Payment of debt issuance costs | NaN | 0 | 371 | NaN |
| Proceeds from exercises of stock options | 19 | 197 | 106 | 253 |
| Proceeds from convertible promissory notes/secured promissory notes payable, related party-Nonrelated Party | NaN | 0 | 0 | 0 |
| Proceeds from convertible promissory notes/secured promissory notes payable, related party-Related Party | NaN | 0 | 0 | 0 |
| Payments to secured promissory notes payable, related party-Related Party | NaN | 0 | NaN | NaN |
| Proceeds from sale of common stock | NaN | 0 | NaN | NaN |
| Payments to factoring | NaN | 0 | NaN | NaN |
| Repayment of principal secured term loan | 1,438 | 1,438 | NaN | NaN |
| Payments of principal on finance leases | 0 | 93 | NaN | 149 |
| Proceeds from factoring, net | NaN | NaN | 0 | 0 |
| Payments of principal on finance lease and extinguishment of lease liability | NaN | NaN | 242 | NaN |
| Net cash used in financing activities | -1,419 | -1,241 | -4,450 | 104 |
| Effect of exchange rates on cash and cash equivalents | 0 | 0 | 0 | 0 |
| Net change in cash and cash equivalents during period | -1,180 | 2,357 | 1,106 | -1,741 |
| Cash and cash equivalents at beginning of period | 11,959 | 9,602 | 10,237 | NaN |
| Cash and cash equivalents at end of period | 10,779 | 11,959 | 9,602 | NaN |